Our governance
The Board of Directors
The Anticancer Fund is led by a Board of Directors with experienced, higher level professionals.
The board meets quarterly to define the strategy, review the financial resources, evaluate the impact and guide the Anticancer Fund in its mission.
It has ultimate responsibility for the fund’s management.
Luc Verelst
- Founder and chairman of the Anticancer Fund
- Read the story of Luc Verelst
Alice Dossche
- International Business Development Manager LessonUp, The Hague (the Netherlands), Member of the Well of Charity: water (US)
- Bachelor of Arts, History and Economics, New York University
Luc Tayart de Borms
- Managing Director of the King Baudouin Foundation, until 30 April 2022
- Master’s degree in Moral Sciences, University of Ghent
Lydie Meheus
- Managing Director of the Anticancer Fund
- PhD in Sciences, University of Ghent
Jo Van Biesbroeck
- Founder of Nadine de Beaufort fund, member of the board of KickCancer, among other.
- Master’s degree in Economics, University of Leuven
Rudy Dekeyser
- Partner EQT and head of the EQT Health Economics Funds, former Co-founder and Managing Director of the Vlaams Instituut voor Biotechnologie (VIB)
- PhD in Molecular Biology, University of Ghent
The Board of Advisors
The Anticancer Fund relies on a group of experts for scientific and strategic advice. They provide assistance on a broad and regular basis, depending on their area of expertise. The members of the Board of Advisors offer their consultancy services pro bono.
Our current Board of Advisors consists of, in alphabetical order:
Erik Briers, MSc, PhD, patient advocate
Sam Daems, economist, patient advocate
Evandro de Azambuja, MD, PhD, oncologist
Robert A. Gatenby, MD, radiologist
Delphine Heenen, LLM, patient advocate
Yolande Lievens, MD, PhD, radiation oncologist
André Mihaljevic, MD, surgical oncologist
Anja Schiel, methodologist in regulatory & pharmacoeconomic statistics
Silvia Stacchiotti, MD, PhD, sarcoma oncologist
Eric Van Cutsem, MD, PhD, digestive oncologist
Joris Verlooy, MD, paediatric hemato-oncologist
In addition to the Board of Advisors, a panel of international experts is helping our research team with the study selection, protocol design and other clinical trial related topics. When seeking advice of an expert, we carefully ensure that there is no direct conflict of interest between their own research and the projects of the Anticancer Fund.